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ABSTRACT: Easy operation, readily accessible starting materials, and short syntheses of the privileged scaffold indeno[1,2-
c]isoquinolinone were achieved by an multicomponent reaction (MCR)-based protocol via an ammonia−Ugi-four component
reaction (4CR)/copper-catalyzed annulation sequence. The optimization and scope and limitations of this short and general
sequence are described. The methodology allows an efficient construction of a wide variety of indenoisoquinolinones in just two
steps.
■ INTRODUCTION
The quest for novel synthetic routes for nitrogen (N)-
containing heterocycles using atom-economical and efficient
pathways is an active field in synthetic chemistry nowadays.
This is due to widespread applications of N-containing
heterocycles in almost all branches of organic chemistry
including active pharmaceutical research,1 functional materi-
als,2 catalysis,3 and coordination chemistry.4 Among the N-
containing heterocycles, the indenoisoquinoline is a highly
valuable scaffold, endowed with inhibition activities against
topoisomerase I (Topo1)5 in clinical testing with improved
physicochemical and biological properties as compared to the
clinically used camptothecin anticancer drugs, topotecan and
irinotecan.6 Several indenoisoquinolines, such as indotecan
(LMP400, Figure 1A), have entered phase I clinical trials.7
The Ugi reaction is one of the most prominent multi-
component reaction (MCR) families.8 It has attracted much
attention due to the possibility of introducing versatile
functional groups in the Ugi adducts, which can undergo
further condensations or cyclization reactions, leading to an
array of structurally diverse scaffolds.9 Specifically, the Ugi
four-component reaction (Ugi-4-CR) utilizing ammonia as the
amine component can be an extremely valuable approach
because it is inexpensive, is easily available, and permits
reduced waste. However, relatively fewer studies have focused
on it, most of which report an excessive byproduct formation
and low yield (Figure 1B−D).10
Nowadays, introducing cleaner, safer, and easier accessible
nitrogen donors to N-containing organic compounds is an
extensively studied topic.11 In 2009, the Chen group reported a
simple, one-step assembly of Ugi adducts suitable for
elaboration into a variety of 5-aminoazole compounds through
postcondensation modifications by employing concentrated
aqueous ammonia as a convenient source (Figure 1B).10
Hutton et al. synthesized ustiloxin D utilizing an ammonia−
Ugi reaction (Figure 1C).12 Recently, Polindara-Garciá and his
colleagues developed a novel protocol for the fast introduction
of the picolinamide directing group in aliphatic ketones using
the ammonia−Ugi 4-CR reaction and the subsequent Pd-
mediated γ-C(sp3)−H bond activation (Figure 1D).13
Ullmann−Hurtley condensations are powerful tools for the
formation of carbon−heteroatom and carbon−carbon bonds in
the construction of a wide variety of heterocycles.14 In 2012,
Zhao et al. reported the synthesis of indolo[2,1-b]quinazoline
derivatives via copper-catalyzed Ullmann-type intermolecular
C−C and intramolecular C−N couplings.14c In 2016, a series
of isoquinoline derivatives were synthesized, with high chemo-
and regioselectivities, via the copper-catalyzed cascade reaction
of 2-haloaryloxime acetates with β-diketones, β-keto esters, and
β-keto nitriles.14f In addition, an Ugi-type MCR/copper-
catalyzed annulation sequence has been an important strategy,
leading to high structural diversity and molecular complexity.15
Inspired by the remarkable progress of this key reaction
achieved and based on our ongoing interest in MCR
chemistry,9,16 we envisioned that indeno[1,2-c]isoquinolinone
derivatives could be alternatively synthesized in a concise
manner by an Ugi reaction of o-halobenzoic acids and
ammonia, followed by a Cu-catalyzed annulation reaction
with 1,3-indandione (Figure 1E).
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■ RESULTS AND DISCUSSION
The Ugi adduct model 5a was readily obtained in 58% yield by
reacting equimolar quantities of 2-iodobenzoic acid 1a,
paraformaldehyde 3a, and tert-butyl isocyanide 4a with an
excess of an aqueous ammonia solution (1.2 equiv) 2 in 2,2,2-
trifluoroethanol (TFE) under 60 °C for 12 h in a closed vial.
Thereafter, we investigated the copper-catalyzed tandem
reaction and optimized the reaction conditions by variation
of the Cu source, base, solvent, time, and temperature (Table
1). When the reaction was carried out with 1,3-indandione 6a
(1 equiv) in the presence of 5 mol % CuCl2 using 2.0 equiv of
K2CO3 as the base in MeCN at 90 °C for 3 h, the desired
product 7aa was obtained in 61% yield (entry 1). Cs2CO3
(65% yield, entry 2) was superior to K2CO3 and was selected
as the base for further studies. To our delight, the desired
product 7aa was formed in 70% yield with the addition of 1.5
equiv of 1,3-indandione 6a (entry 3). Increasing the amount of
6a to 2.0 equiv afforded 7aa in 68% yield (entry 4). However,
replacing the catalyst with CuI, CuSO4, CuCl, CuBr, CuBr2,
Cu(NO3)2, Cu2O, and CuCN resulted in lower yields of 7aa of
49, 32, 44, 23, 25, 36, 64, and 57%, respectively (entries 5−
12). The yield of 7aa decreased to 62% at a temperature of 80
°C (entry 13). Also, a higher temperature of 100 °C did not
increase the yield (entry 14). Variation of solvents yielded the
following: a moderate yield of the product was obtained (42%)
when dioxane was chosen as the solvent (entry 15), while no
reaction at all occurred when toluene was used (entry 16).
Moreover, a trace amount of products was produced in polar
aprotic solvents such as dimethylformamide (DMF) and
dimethyl sulfoxide (DMSO) (entries 17 and 18). Finally,
MeCN was the best solvent for this reaction among the
selected solvents (entry 3 vs entries 15−18). Decreasing and
increasing the reaction time did not help in improving the
outcome of the product (entries 19 and 20). Notably, 35%
yield was obtained when the reaction was run in the microwave
irritation for 1 h (entry 21). Finally, the optimized reaction
conditions were concluded to be the Ugi intermediate 5a (0.3
mmol), 1,3-indandione 6a (0.45 mmol), 5 mol % CuCl2, and
2.0 equiv of Cs2CO3 in MeCN (4 mL) at 90 °C for 3 h (entry
3).
With the optimal conditions in hand, a set of Ugi products
were synthesized in moderate to good yields and were
examined to determine the scope of the tandem reaction to
furnish the corresponding products 7a−t (Scheme 1). All of
the substrates 1−6 led to the expected indeno[1,2-c]-
isoquinolinone products 7a−t in just two simple steps. We
initially replaced 1,3-indanedione with 5,6-dimethoxy-1,3-
indanedione, and the reaction proceeded smoothly to afford
the corresponding indenoisoquinoline derivatives in good yield
(7ab). Paraformaldehyde was utilized in many cases and
resulted in moderate to good yields (7a−e, 7n, 7t). Further,
various aliphatic aldehydes including acetaldehyde (7f),
isobutyraldehyde (7g), butyraldehyde (7h), 3-methylbutanal
(7i), cyclopentanecarbaldehyde (7j), 3-phenylpropanal (7k),
and 3-(methylthio)propanal (7r) proceeded well in this MCR
Figure 1. (A) Clinical Topo1 inhibitor LMP-400; (B) Ugi reactions with ammonia, yielding 5-aminothiazole and oxazole derivatives; (C) synthesis
of ustiloxin D utilizing an ammonia−Ugi reaction; (D) Pd-mediated C(sp3)−H bond activation in ammonia−Ugi 4-CR adducts; and (E) our work:
copper-catalyzed arylation of 1,3-indandione of ammonia−Ugi 4-CR adducts.
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and tandem reaction. We found that aromatic aldehydes
bearing weak electron-withdrawing groups such as 4-Br and 4-
Cl led to derivatives 7o and 7s in good yields. Similarly, the use
of benzaldehyde and an electron-donating group 4-OMe in the
aromatic aldehyde was compatible in this process to deliver the
products in good yields (7p, 7m). Heterocyclic pyridine
aldehydes demonstrated good behavior in the Cu-mediated
reaction and furnished 7q in good yield (65%). In addition,
commercially available 5-methoxy-, 4-methoxy-, 5-methyl-, 4-
methyl-, and 4-nitro-substituted 2-bromobenzoic acid reacted
to give the expected product 7n−t in moderate to good yields.
After successfully demonstrating the cyclization reactions
with different aldehydes and 2-halogenbenzoic acids, we then
examined indandione with various Ugi adducts by simply
changing the isocyanide pool in the MCR and then studying
the subsequent annulation. Benzyl isocyanide (7d, 7j, 7n) and
substituted benzyl isocyanides with electron-donating and
-withdrawing groups like 4-chloro (7e), 2,3-dimethoxy (7i)
and 4-cyano (7p) reacted smoothly with 40, 75, 62, 80, 72, and
35% yields, respectively. Isocyanobenzene containing valuable
functional groups such as ethyl and anisole was also applied
and gave the corresponding products in good yields (7h, 7f).
Similarly, (2-isocyanoethyl)benzene (7o) and methyl 2-
isocyanoacetate (7l) also furnished the different indeno[1,2-
c]isoquinolinone products in 49 and 59% yields, respectively.
In addition, aliphatic linear (7b), cyclic (7c) and branched
isocyanides like tert-butyl isocyanide (7a, 7g, 7m, 7q−t) and
tert-octyl isocyanide (7k) also yielded different tetrahetero-
cycles. Scheme 1 clearly indicates that there are no electronic
or steric effects on the outcome of the reaction.
We also introduced ortho halo heterocyclic carboxylic acids
such as 2-chloroquinoline-3-carboxylic acid and 2-bromothio-
phene-3-carboxylic acid in the Ugi reaction, which reacted with
25% ammonia solution 2, paraformaldehyde 3a, and tert-butyl
isocyanide 4a instead of a benzoic acid component to deliver
products 5u and 5v. Following the present protocol, it is
interesting that under optimized reaction conditions, the
former substrate 5u provided the corresponding pentacyclic
multiheterocyclic compound N-(tert-butyl)-2-(6,13-dioxo-
6,13-dihydro-5H-benzo[b]indeno[1,2-h][1,6]naphthyridin-5-
yl)acetamide (7u) in good yield. However, the latter substrate
5v afforded the tetracyclic compound N-(tert-butyl)-2-(4,10-
dioxo-4,10-dihydro-5H-indeno[1,2-b]thieno[2,3-d]pyridin-5-
yl)acetamide (7v) in moderate yield (Scheme 2).
Furthermore, the scalability of this method was investigated
(Scheme 3A). A four-component reaction of 2-iodobenzoic
acid, ammonia, cyclopentanecarbaldehyde, and benzyl iso-
cyanide was conducted on a 5 mmol scale, which further
reacted with 1,3-indandione, while the polyheterocyclic
product 7j could be obtained in 40% overall yield (0.93 g).
To further underscore the usefulness of the herein described
indeno[1,2-c]isoquinolinones, we performed several late-stage
functionalizations (Scheme 3). The bromo group of 7o was
coupled with (2,3-dihydrobenzo[b][1,4]dioxin-6-yl)boronic
acid to give the derivate 8 by a Suzuki reaction (Scheme
3B). In another application, product 7p was reacted with
sodium azide to afford tetrazole 9 in good yield (Scheme 3C).
Finally, while reducing the nitro group of product 7t with Pd/
C, a mixture of 10 and the major overreductive product 11
(Supporting Information) was obtained. Therefore, we chose
SnCl2 for the selective reduction of a nitro group to deliver 10
in excellent yield (96%) and used it for further coupling
(Scheme 3D). The intriguing scaffold urea 12 was successfully
achieved by reacting 10 with (isocyanatomethyl)benzene in a
cosolvent system.17 In addition, we also coupled 10 with Boc-
L-phenylalanine to afford a starting point for peptide synthesis.
This effort was initially hindered by the lack of reactivity of 10




(HATU), 1′-carbonyldiimidazole (CDI), etc.). A phosphorous
oxychloride-mediated amide-bond-forming protocol was uti-
lized for the formation of the desired product 13 in good
yield.18 Such kind of derivatives could be potentially useful as
fluorescent tags to follow a peptide in biological material.
The crystal structure of compound 7aa is shown in Figure 2,
which unambiguously supports our chemistry (Figure 2). The
structure features the high planarity of the tetracyclic structure
and an intermolecular hydrogen bonding between two adjacent
molecules.
A plausible mechanism of this tandem reaction is
hypothesized and shown in Scheme 4. The reaction is
presumably initiated with the reaction of Cu(I) active species,
which was present in copper salts and 1,3-indandione 6a to
produce intermediate A, and the oxidative addition of the Ugi
adduct 2-iodo-N-phenylbenzamide 5a to this copper(I)
complex results in the formation the Cu(III) intermediate B,
which is further converted into intermediate C via reductive
elimination. The intramolecular addition of the amide nitrogen
to the carbonyl group in intermediate C gives intermediate D,
which is then converted into 7aa by dehydration.
Table 1. Optimization of Reaction Conditionsa,b
aReaction conditions: 5a (0.3 mmol), 6a, catalyst (5 mmol %), base
(0.6 mmol), solvent (4 mL). bTFE = 2,2,2-trifluoroethanol. cIsolated
yields. dN.D. = not detected. eMicrowave. Green color indicates best
condition screened.
The Journal of Organic Chemistry pubs.acs.org/joc Article
https://dx.doi.org/10.1021/acs.joc.0c01238
J. Org. Chem. 2020, 85, 9915−9927
9917
Scheme 1. Ammonia−Ugi Reaction and the Subsequent Copper-Catalyzed Tandem Reactiona,b,c
aThe Ugi reaction was carried out using 1 (2.0 mmol), 2 (2.4 mmol), 3 (2.0 mmol), and 4 (2.0 mmol) in CF3CH2OH (1.0 M) for 12 h at 60 °C.
bReaction conditions: 5 (0.3 mmol), 6 (0.45 mmol), Cs2CO3 (0.6 mmol), CuCl2 (0.015 mmol), CH3CN (4 mL), 90 °C, 3 h.
cYield refers to the
purified products. First yield refers to the Ugi reaction and second yield to the cyclization.
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Scheme 2. Synthesis of Heterocyclic Fused Indenopyridone Derivatives
Scheme 3. Gram-Scale Reaction and Synthetic Applications
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■ CONCLUSIONS
Our work features the development of an efficient route for the
synthesis of a bioactive indenoisoquinoline library by
incorporating a copper-catalyzed tandem reaction with the
step-economical, high-yielding ammonia−Ugi MCR. Diversity
can be achieved through the aldehyde, isocyanide, and 2-
halogen benzoic acid components. This protocol offers a rapid
approach to the indenoisoquinolinone scaffold, along with the
achievement of remarkable structural diversity and brevity. The
process is a simple operation, which uses readily available
starting materials and provides good scalability. Furthermore,
the current protocol was successfully extended to the synthesis
of other benzo-1,4-dioxane-, urea-, and peptide-containing and
tetrazolo indenoisoquinolinone cores, thus aiding future
structure−activity relationship (SAR) studies for discovering
potent and selective Topo1 inhibitors.
■ EXPERIMENTAL SECTION
General Information. Nuclear magnetic resonance spectra were
recorded on a Bruker Avance 500 spectrometer. Chemical shifts for
1H NMR are reported relative to tetramethylsilane (TMS) (δ 0 ppm)
or an internal solvent peak (CDCl3 δ 7.26 ppm, CD3OD δ 3.31 ppm
or D2O δ 4.79 ppm), and coupling constants are in hertz (Hz). The
following abbreviations were used for spin multiplicity: s = singlet, d =
doublet, t = triplet, dt = double triplet, ddd = doublet of double
doublet, m = multiplet, and br = broad. Chemical shifts for 13C NMR
are reported in parts per million (ppm) relative to the solvent peak
(CDCl3 δ 77.23 ppm, DMSO δ 39.52 ppm, CD3OD δ 49.00 ppm).
Filtrations were performed on a silica bed (Screening Devices BV,
60−200 μm, 60 Å). Flash chromatography was performed on a Grace
Reveleris X2 using Grace Reveleris silica columns (12 g), and a
gradient of petroleum ether/ethyl acetate (0−100%) or dichloro-
methane/methanol (0−20%) was applied. Thin-layer chromatog-
raphy (TLC) was performed on Fluka precoated silica gel plates (0.20
mm thick, particle size 25 μm). Reagents were available from
commercial suppliers and used without any purification unless
otherwise noted. All isocyanides were made in house by performing
the Ugi procedure. Other reagents were purchased from Sigma-
Aldrich, ABCR, Acros, Fluorochem, and AK Scientific and were used
without further purification. Mass spectra were recorded on a Waters
investigator supercritical fluid chromatograph with a 3100 MS
detector (electrospray ionization (ESI)) using a solvent system of
methanol and CO2 on a Viridis silica gel column (4.6 × 250 mm
2, 5
μm particle size) and are reported as (m/z). High-resolution mass
spectra (HRMS) were recorded using an LTQ-Orbitrap-XL (Thermo
Fisher Scientific; ESI pos. mode) at a resolution of 60 000@m/z400.
Melting points were obtained on a melting point apparatus and were
uncorrected. Yields given refer to chromatographically purified
compounds unless otherwise stated.
General Experimental Procedure and Characterization.
General Procedure A. A calculated volume of a 25% ammonia
solution (2.4 mmol) was added to a stirred solution or suspension of
the carboxylic acid (2 mmol) in 2,2,2-trifluoroethanol (2 mL). The
aldehyde (2 mmol) and isocyanide (2 mmol) were then introduced,
and stirring was continued at 60 °C in a close screwed vial in a heating
metal block overnight. The solvent was removed by rotary
evaporation, and the crude product was purified by column
chromatography to give the desired product 5.
General Procedure B. Ugi adduct 5 (0.3 mmol), indandione 6
(0.45 mmol), and Cs2CO3 (0.6 mmol) were added to a 10 mL round-
bottom flask equipped with a magnetic stir bar, and 4 mL of
acetonitrile was added. The mixture was heated to 90 °C in an oil
bath for 5 min, and then CuCl2 (0.0015 mmol) was added and
reacted for 3 h. The progress of the reaction was monitored by TLC
for the disappearance of 5. After the reaction was completed, the
solvent was removed by rotary evaporation and the crude was product
purified by column chromatography to give the desired product 7.
Gram-Scale Synthesis of 7j. An oven-dried 50 mL flask equipped
with a magnetic stirrer bar was charged with a calculated volume of a
25% ammonia solution (5.5 mmol) and 2-iodobenzoic acid (5 mmol)
in 2,2,2-trifluoroethanol (5 mL). Then, cyclopentanecarbaldehyde (5
mmol) and benzyl isocyanide (5 mmol) were added to the solution
and the reaction mixture was stirred at 60 °C in an oil bath overnight.
The Ugi adduct 5j was filtered and was then added to indandione 6a
Figure 2. Crystal structure of 7aa (CCDC 1991899) featuring a
dimer and an intermolecular hydrogen bond between the NH of one
molecule and the CO of the neighboring molecule of 2.1 Å length.
Scheme 4. Plausible Reaction Mechanism
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(1.5 equiv) and Cs2CO3 (2 equiv) in acetonitrile (1.3 M) and heated
to 90 °C in an oil bath for 5 min. Then, CuCl2 (10 mol %) was added
and reacted for 5 h. The progress of the reaction was monitored by
TLC for the disappearance of 5j. After the reaction was completed,
the solvent was removed by rotary evaporation and the crude product
was purified by column chromatography (silica gel, petroleum ether/
ethyl acetate = 3:2) to afford the product 7j (0.93 g, 40% yield).
Procedure C. Compound 7o (0.1 mmol) and (2,3-dihydrobenzo-
[b][1,4]dioxin-6-yl)boronic acid (0.15 mmol) were placed in a 25 mL
round-bottom flask, and toluene/ethanol (v/v = 5:1) (3 mL) and sat.
NaHCO3 (3 mL) were added. The mixture was flushed by N2 for 10
min. Then, Pd(dppf)Cl2 (0.01 mmol) was added and the reaction
mixture was allowed to react at 90 °C in an oil bath for 12 h. Then,
the reaction mixture was cooled to room temperature and treated with
H2O and extracted with EtOAc. The combined organic layers were
washed with brine and dried over anhydrous Na2SO4. After the
removal of EtOAc, the residue was purified by column chromatog-
raphy (silica gel, petroleum ether/ethyl acetate = 1:1) to afford the
product 8.
Procedure D. Compound 7p (0.1 mmol), NaN3 (0.12 mmol), and
NH4Cl (0.12 mmol) in DMF (1 mL) were placed in a closed 4 mL
screwcap glass vial and heated in a heating metal block at 100 °C for
18 h. DMF was removed under vacuum, and the residue was purified
by column chromatography (silica gel, methanol/dichloromethane =
1:4) to afford the product 9.
Procedure E. To a flask were added 7t (0.2 mmol), HCOONH4 (2
mmol), and 10% Pd/C (10 mg). Anhydrous ethanol (4 mL) was
added as a solvent, and the reaction mixture was stirred at room
temperature for 8 h. The mixture was filtered, and the filtrate was
concentrated under vacuum. The residue was purified by silica gel
column chromatography using ethyl acetate/petroleum ether (v/v,
3:2) as an eluent to give product 10 (26 mg, 35% yield) as a red solid,
and 2-(2-amino-5,11-dioxo-5,6a,11,11a-tetrahydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)-N-(tert-butyl)acetamide 11 (44 mg, 58% yield) was
obtained using ethyl acetate/petroleum ether (v/v, 4:1) as an eluent
as a white solid.
Procedure F. To a solution of 7t (0.3 mmol) in EtOH (1 mL) was
added SnCl2 (1.5 mmol) at 0 °C, and the resulting mixture was stirred
at room temperature for 10 min and then refluxed in an oil bath for 4
h. After the completion of the reaction, ice-cold water was added to
the reaction mixture. The obtained residue was diluted with a 20%
NaOH solution, and the aqueous layer was extracted with EtOAc.
The organic layer was dried with MgSO4 and concentrated to provide
the product 10 (108 mg, 96% yield).
Procedure G. Compound 10 (0.1 mmol) was dissolved in a solvent
mixture of dry DMF and THF (1:4 v/v) (1 mL) in a 10 mL round-
bottom flask. To this solution was added phenyl isocyanate (0.15
mmol), and the mixture stirred under an inert atmosphere at 90 °C in
an oil bath for 8 h. The reaction mixture was cooled to room
temperature. Solvents was removed under vacuum, and the residue
was purified by column chromatography (silica gel, petroleum ether/
ethyl acetate = 3:7) to afford the product 12 (32 mg, 64% yield).
Procedure H. Boc-L-phenylalanine (0.1 mmol) and compound 10
(0.1 mmol) were dissolved in dry pyridine (0.3 mL). The solution
was cooled to −15 °C, and phosphorus oxychloride (0.11 mmol) was
added dropwise with vigorous stirring. The reaction was completed
after 30 min (monitored by TLC). The reaction mixture was then
quenched with crushed ice/water (10 mL) and extracted with EtOAc
(three times, 10 mL). The combined EtOAc layers were washed with
saturated NaHCO3 and NaCl (three times, 10 mL each). After being
dried on Na2SO4, the EtOAc layer was filtered and evaporated in
vacuo. The residue was purified by column chromatography (silica
gel, petroleum ether/ethyl acetate = 1:1) to afford the product 13 (49
mg, 78% yield).
N-(2-(tert-Butylamino)-2-oxoethyl)-2-iodobenzamide (5a). It
was synthesized according to procedure A on a 2 mmol scale (418
mg, 58%) as a white solid; mp: 178−179 °C; Rf = 0.58 (50% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.82 (dd, J =
13.1, 7.6 Hz, 1H), 7.42−7.30 (m, 3H), 7.08 (ddd, J = 10.8, 6.6, 2.7
Hz, 1H), 6.89−6.70 (m, 1H), 4.08 (t, J = 4.7 Hz, 2H), 1.33 (d, J =
12.3 Hz, 9H). 13C{1H} NMR (126 MHz, chloroform-d) δ 169.8,
167.9, 141.3, 139.9, 131.3, 128.4, 128.1, 92.6, 51.6, 44.6, 28.8. HRMS
(ESI) m/z: [M + H]+ calcd for C13H18IN2O2, 361.0408; found,
361.0407.
N-(2-(Butylamino)-2-oxoethyl)-2-iodobenzamide (5b). It was
synthesized according to procedure A on a 2 mmol scale (353 mg,
49%) as a yellow solid; mp: 195−196 °C; Rf = 0.38 (50% EtOAc/
dichloromethane). 1H NMR (500 MHz, chloroform-d) δ 7.88 (d, J =
7.9 Hz, 1H), 7.40 (q, J = 7.9 Hz, 2H), 7.13 (t, J = 7.7 Hz, 1H), 6.98
(s, 1H), 6.75 (s, 1H), 4.17 (d, J = 5.2 Hz, 2H), 3.29 (q, J = 6.8 Hz,
2H), 1.56−1.48 (m, 2H), 1.36 (q, J = 7.5 Hz, 2H), 0.91 (t, J = 7.4 Hz,
3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 169.8, 168.4, 141.1,
139.9, 137.7, 131.5, 128.7, 128.4, 128.2, 128.0, 127.6, 92.5, 43.9, 43.7.
13C{1H} NMR (126 MHz, chloroform-d) δ 169.7, 168.3, 141.2,
140.0, 131.5, 128.4, 128.2, 92.5, 43.9, 39.5, 31.5, 20.1, 13.8. HRMS
(ESI) m/z: [M + H]+ calcd for C13H18IN2O2, 361.0408; found,
361.0407.
N-(2-(Cyclohexylamino)-2-oxoethyl)-2-iodobenzamide (5c). It
was synthesized according to procedure A on a 2 mmol scale (347
mg, 45%) as an off-white solid; mp: 160−161 °C; Rf = 0.32 (70%
EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.86
(d, J = 7.9 Hz, 1H), 7.46−7.33 (m, 2H), 7.12 (ddt, J = 9.4, 7.2, 3.6
Hz, 2H), 6.75 (d, J = 8.0 Hz, 1H), 4.13 (d, J = 5.2 Hz, 2H), 3.84−
3.54 (m, 1H), 1.96−1.82 (m, 2H), 1.70 (dt, J = 13.5, 3.9 Hz, 2H),
1.60 (dt, J = 12.9, 3.9 Hz, 1H), 1.38−1.25 (m, 3H), 1.24−1.11 (m,
3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 169.8, 167.4, 141.3,
139.9, 131.4, 128.4, 128.2, 92.6, 48.6, 44.0, 32.9, 25.5, 24.8. HRMS
(ESI) m/z: [M + H]+ calcd for C15H20IN2O2, 387.0564; found,
387.0565.
N-(2-(Benzylamino)-2-oxoethyl)-2-iodobenzamide (5d). It was
synthesized according to procedure A on a 2 mmol scale (284 mg,
36%) as a yellow solid; mp: 143−144 °C; Rf = 0.34 (70% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.85 (d, J =
7.9 Hz, 1H), 7.37 (d, J = 4.8 Hz, 2H), 7.33−7.24 (m, 5H), 7.12 (dt, J
= 8.4, 4.3 Hz, 2H), 6.92 (s, 1H), 4.46 (d, J = 4.7 Hz, 2H), 4.28−3.95
(m, 2H). 13C{1H} NMR (126 MHz, chloroform-d) δ 169.8, 168.4,
141.1, 139.9, 137.7, 131.5, 128.7, 128.4, 128.2, 128.0, 127.6, 92.5,
43.9, 43.7. HRMS (ESI) m/z: [M + H]+ calcd for C16H16IN2O2,
395.0251; found, 395.0246.
N-(2-((4-Chlorobenzyl)amino)-2-oxoethyl)-2-iodobenzamide
(5e). It was synthesized according to procedure A on a 2 mmol scale
(512 mg, 60%) as a yellow solid; mp: 166−167 °C; Rf = 0.22 (80%
EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.82
(d, J = 8.0 Hz, 1H), 7.65 (s, 1H), 7.33 (p, J = 7.3 Hz, 2H), 7.24−7.15
(m, 5H), 7.10 (t, J = 7.2 Hz, 1H), 4.36 (s, 2H), 4.30−3.93 (m, 2H).
13C{1H} NMR (126 MHz, chloroform-d) δ 169.9, 168.6, 140.9,
140.0, 136.4, 133.2, 131.5, 129.2, 128.7, 128.3, 128.2, 92.6, 43.9, 42.9.
HRMS (ESI) m/z: [M + H]+ calcd for C16H15ClIN2O2, 428.9861;
found, 428.9860.
2-Iodo-N-(1-oxo-1-((4-phenoxyphenyl)amino)propan-2-yl)-
benzamide (5f). It was synthesized according to procedure A on a 2
mmol scale (369 mg, 38%) as a yellow solid; mp: 178−179 °C; Rf =
0.65 (50% EtOAc/petroleum ether). 1H NMR (500 MHz, chloro-
form-d) δ 9.36 (s, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.56 (d, J = 8.5 Hz,
2H), 7.45−7.37 (m, 2H), 7.33 (t, J = 7.9 Hz, 2H), 7.17−7.05 (m,
3H), 6.97 (dd, J = 20.7, 8.3 Hz, 4H), 5.11 (t, J = 7.2 Hz, 1H), 1.64 (d,
J = 6.5 Hz, 3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 170.0,
169.7, 157.6, 153.4, 141.0, 140.0, 133.5, 131.6, 129.7, 128.3 (d, J = 3.2
Hz), 123.0, 121.7, 119.6, 118.4, 92.5, 50.3, 18.4. HRMS (ESI) m/z:
[M + H]+ calcd for C22H20IN2O3, 487.0513; found, 487.0512.
N-(1-(tert-Butylamino)-3-methyl-1-oxobutan-2-yl)-2-iodobenza-
mide (5g). It was synthesized according to procedure A on a 2 mmol
scale (322 mg, 40%) as a white solid; mp: 234−235 °C; Rf = 0.51
(20% EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d)
δ 7.89 (d, J = 8.0 Hz, 1H), 7.48−7.36 (m, 2H), 7.12 (ddd, J = 8.0, 6.3,
2.9 Hz, 1H), 6.64 (d, J = 8.8 Hz, 1H), 5.92 (s, 1H), 4.29 (dd, J = 8.8,
7.1 Hz, 1H), 2.19 (h, J = 6.8 Hz, 1H), 1.39 (s, 9H), 1.06 (dd, J = 10.8,
6.8 Hz, 6H). 13C{1H} NMR (126 MHz, chloroform-d) δ 169.7, 169.2,
141.8, 140.0, 131.2, 128.3, 128.1, 92.4, 59.7, 51.8, 31.3, 28.8, 19.3,
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18.6. HRMS (ESI) m/z: [M + H]+ calcd for C16H24IN2O2, 403.0877;
found, 403.0872.
N-(1-((2-Ethylphenyl)amino)-1-oxopentan-2-yl)-2-iodobenza-
mide (5h). It was synthesized according to procedure A on a 2 mmol
scale (486 mg, 54%) as a yellow solid; mp: 190−191 °C; Rf = 0.48
(30% EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d)
δ 8.10 (s, 1H), 7.93−7.89 (m, 1H), 7.86 (dd, J = 8.0, 1.5 Hz, 1H),
7.44−7.37 (m, 2H), 7.24 (t, J = 7.7 Hz, 2H), 7.19−7.12 (m, 2H),
6.45 (d, J = 8.0 Hz, 1H), 4.83 (td, J = 7.7, 6.4 Hz, 1H), 2.69 (qd, J =
7.5, 3.3 Hz, 2H), 2.19−2.05 (m, 1H), 1.93−1.80 (m, 1H), 1.61−1.55
(m, 2H), 1.27 (t, J = 7.6 Hz, 3H), 1.05 (t, J = 7.3 Hz, 3H). 13C{1H}
NMR (126 MHz, chloroform-d) δ 169.8, 169.4, 141.3, 140.0, 135.3,
134.7, 131.5, 128.7, 128.3, 126.6, 125.7, 123.5, 92.3, 54.4, 33.7, 24.4,
19.1, 14.1, 13.9. HRMS (ESI) m/z: [M + H]+ calcd for C20H24IN2O2,
451.0877; found, 451.0876.
N-(1-((2,3-Dimethoxybenzyl)amino)-4-methyl-1-oxopentan-2-
yl)-2-iodobenzamide (5i). It was synthesized according to procedure
A on a 2 mmol scale (398 mg, 39%) as a yellow solid; mp: 156−157
°C; Rf = 0.45 (50% EtOAc/petroleum ether).
1H NMR (500 MHz,
chloroform-d) δ 7.97−7.68 (m, 1H), 7.38−7.31 (m, 2H), 7.08 (ddd, J
= 8.0, 6.5, 2.6 Hz, 1H), 7.03−6.95 (m, 2H), 6.90 (dd, J = 7.7, 1.6 Hz,
1H), 6.86 (dd, J = 8.2, 1.5 Hz, 1H), 6.57 (d, J = 8.6 Hz, 1H), 4.73 (td,
J = 8.4, 8.0, 5.0 Hz, 1H), 4.48 (d, J = 5.7 Hz, 2H), 3.87 (d, J = 1.7 Hz,
6H), 1.86−1.71 (m, 2H), 1.72−1.63 (m, 1H), 0.97 (dd, J = 10.4, 6.2
Hz, 6H). 13C{1H} NMR (126 MHz, chloroform-d) δ 171.3, 169.3,
152.6, 147.2, 141.7, 139.8, 131.5, 131.2, 128.2, 128.1, 124.2, 121.4,
112.0, 92.4, 60.8, 55.8, 52.2, 41.1, 38.8, 24.9, 23.0, 22.2. HRMS (ESI)
m/z: [M + H]+ calcd for C22H28IN2O4, 511.1088; found, 511.1083.
N-(2-(Benzylamino)-1-cyclopentyl-2-oxoethyl)-2-iodobenzamide
(5j). It was synthesized according to procedure A on a 2 mmol scale
(573 mg, 62%) as a yellow solid; mp: 205−206 °C; Rf = 0.54 (50%
EtOAc/petroleum ether). 1H NMR (500 MHz, DMSO-d6) δ 8.56 (d,
J = 8.4 Hz, 1H), 8.50 (t, J = 6.0 Hz, 1H), 7.88 (d, J = 7.8 Hz, 1H),
7.45 (t, J = 7.5 Hz, 1H), 7.38−7.28 (m, 5H), 7.27−7.22 (m, 1H),
7.17 (td, J = 7.6, 1.7 Hz, 1H), 4.38 (d, J = 6.0 Hz, 1H), 4.35−4.29 (m,
2H), 2.28 (q, J = 8.2 Hz, 1H), 1.79 (m, J = 13.8, 4.8 Hz, 1H), 1.70−
1.55 (m, 3H), 1.49 (m, J = 7.1, 3.0 Hz, 2H), 1.45−1.37 (m, 2H).
13C{1H} NMR (126 MHz, DMSO-d6) δ 171.5, 169.1, 143.3, 139.9,
139.5 (d, J = 3.9 Hz), 131.2, 128.7, 128.3, 127.7, 127.2, 93.9, 57.8 (d,
J = 3.9 Hz), 42.5, 42.0, 29.7, 29.4, 25.4, 25.1. HRMS (ESI) m/z: [M +
H]+ calcd for C21H24IN2O2, 463.0877; found, 463.0876.
2-Iodo-N-(1-oxo-4-phenyl-1-((2,4,4-trimethylpentan-2-yl)-
amino)butan-2-yl)benzamide (5k). It was synthesized according to
procedure A on a 2 mmol scale (572 mg, 55%) as a yellow solid; mp:
157−158 °C; Rf = 0.46 (20% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 7.87 (dt, J = 8.0, 1.4 Hz, 1H), 7.41−7.27
(m, 4H), 7.22 (d, J = 7.3 Hz, 3H), 7.11 (ddd, J = 7.6, 5.6, 1.8 Hz,
1H), 6.95 (t, J = 18.8 Hz, 1H), 6.48 (d, J = 36.1 Hz, 1H), 4.98−4.49
(m, 1H), 2.80 (dt, J = 9.4, 6.2 Hz, 2H), 2.37−2.16 (m, 1H), 2.18−
2.00 (m, 1H), 1.86 (dd, J = 14.8, 1.2 Hz, 1H), 1.79−1.55 (m, 1H),
1.43 (t, J = 3.3 Hz, 6H), 1.00 (d, J = 2.0 Hz, 9H). 13C{1H} NMR
(126 MHz, chloroform-d) δ 169.8, 169.1, 141.5, 141.2, 140.0, 131.3,
128.6, 128.5, 128.3, 128.1, 126.1, 92.6 (d, J = 3.2 Hz), 55.6, 54.0, 51.7,
34.3 (d, J = 3.6 Hz), 31.9, 31.7, 31.5, 29.3 (d, J = 2.7 Hz), 28.9.
HRMS (ESI) m/z: [M + H]+ calcd for C25H34IN2O2, 521.1665;
found, 521.1655.
Methyl (2-(2-Iodobenzamido)-2-phenylacetyl)glycinate (5l). It
was synthesized according to procedure A on a 2 mmol scale (307
mg, 34%) as a yellow solid; mp: 159−160 °C; Rf = 0.32 (50% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.88 (dd, J =
8.0, 1.1 Hz, 1H), 7.57−7.52 (m, 2H), 7.47−7.35 (m, 5H), 7.18 (d, J =
6.9 Hz, 1H), 7.12 (td, J = 7.6, 1.8 Hz, 1H), 6.49 (t, J = 5.4 Hz, 1H),
5.76 (d, J = 6.7 Hz, 1H), 4.20−3.99 (m, 2H), 3.75 (s, 3H). 13C{1H}
NMR (126 MHz, chloroform-d) δ 169.9, 169.7, 168.6, 141.0, 140.0,
137.1, 131.4, 129.1, 128.7, 128.6, 128.1, 127.7, 92.4, 57.6, 52.5, 41.5.
HRMS (ESI) m/z: [M + H]+ calcd for C18H18IN2O4, 453.0306;
found, 453.0304.
N-(2-(tert-Butylamino)-1-(4-methoxyphenyl)-2-oxoethyl)-2-iodo-
benzamide (5m). It was synthesized according to procedure A on a 2
mmol scale (354 mg, 38%) as a yellow solid; mp: 197−198 °C; Rf =
0.2 (30% EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-
d) δ 7.85 (dd, J = 7.9, 1.1 Hz, 1H), 7.46 (d, J = 8.7 Hz, 2H), 7.41−
7.30 (m, 3H), 7.15−7.04 (m, 1H), 6.87 (d, J = 8.7 Hz, 2H), 6.40 (s,
1H), 5.76 (d, J = 7.2 Hz, 1H), 3.80 (s, 3H), 1.26 (s, 9H). 13C{1H}
NMR (126 MHz, chloroform-d) δ 169.0, 168.5, 159.4, 141.4, 139.9,
131.2, 130.5, 128.8, 128.4, 128.1, 114.2, 92.5, 57.0, 55.3, 51.7, 28.5.
HRMS (ESI) m/z: [M + H]+ calcd for C20H24IN2O3, 467.0826;
found, 467.0824.
N-(2-(Benzylamino)-2-oxoethyl)-2-bromo-5-methoxybenzamide
(5n). It was synthesized according to procedure A on a 2 mmol scale
(316 mg, 42%) as a yellow solid; mp: 153−154 °C; Rf = 0.5 (80%
EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 7.40
(dd, J = 14.2, 7.9 Hz, 3H), 7.33−7.14 (m, 5H), 6.96 (d, J = 3.1 Hz,
1H), 6.79 (dd, J = 8.8, 3.0 Hz, 1H), 4.38 (d, J = 5.7 Hz, 2H), 4.13 (d,
J = 5.3 Hz, 2H), 3.74 (s, 3H). 13C{1H} NMR (126 MHz, chloroform-
d) δ 168.5, 168.0, 158.8, 137.8, 137.6, 134.1, 128.6, 127.7, 127.5,
117.8, 114.6, 109.6, 55.6, 43.7, 43.6. HRMS (ESI) m/z: [M + H]+
calcd for C17H18BrN2O3, 377.0495; found, 377.0496.
2-Bromo-N-(1-(4-bromophenyl)-2-oxo-2-(phenethylamino)-
ethyl)-5-methoxybenzamide (5o). It was synthesized according to
procedure A on a 2 mmol scale (555 mg, 51%) as a yellow solid; mp:
191−192 °C; Rf = 0.48 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 7.71 (d, J = 6.6 Hz, 1H), 7.54−7.43 (m,
3H), 7.37−7.26 (m, 2H), 7.21 (dd, J = 5.2, 1.9 Hz, 3H), 7.07 (d, J =
3.1 Hz, 1H), 7.00−6.93 (m, 2H), 6.86 (dd, J = 8.8, 3.1 Hz, 1H), 6.47
(t, J = 5.9 Hz, 1H), 5.66 (d, J = 6.6 Hz, 1H), 3.80 (s, 3H), 3.59 (dt, J
= 13.3, 6.7 Hz, 1H), 3.36 (dtd, J = 12.2, 7.0, 5.2 Hz, 1H), 2.69 (td, J =
6.9, 2.2 Hz, 2H). 13C{1H} NMR (126 MHz, chloroform-d) δ 168.9,
166.6, 158.9, 138.3, 137.1, 136.9, 134.4, 132.1, 129.1, 128.6, 128.6,
126.5, 122.5, 118.0, 115.1, 109.7, 57.2, 55.7, 41.0, 35.3. HRMS (ESI)
m/z: [M + H]+ calcd for C24H23Br2N2O3, 545.0070; found, 545.0071.
2-Bromo-N-(2-((4-cyanobenzyl)amino)-2-oxo-1-phenylethyl)-4-
methoxybenzamide (5p). It was synthesized according to procedure
A on a 2 mmol scale (610 mg, 64%) as a white solid; mp: 193−194
°C; Rf = 0.58 (66% EtOAc/petroleum ether).
1H NMR (500 MHz,
chloroform-d) δ 8.03 (t, J = 5.9 Hz, 1H), 7.79 (d, J = 7.3 Hz, 1H),
7.55 (dd, J = 6.6, 2.9 Hz, 2H), 7.40 (t, J = 8.5 Hz, 3H), 7.37−7.33 (m,
3H), 7.13−7.02 (m, 3H), 6.79 (dd, J = 8.7, 2.5 Hz, 1H), 6.13 (d, J =
7.4 Hz, 1H), 4.41 (dd, J = 15.8, 6.0 Hz, 1H), 4.27 (dd, J = 15.8, 5.6
Hz, 1H), 3.84 (s, 3H). 13C{1H} NMR (126 MHz, chloroform-d) δ
170.2, 166.8, 161.6, 143.4, 137.8, 132.2, 131.1, 129.0, 128.5, 128.1,
127.8, 127.2, 120.6, 119.0, 118.7, 113.3, 110.8, 57.5, 55.8, 43.0.
HRMS (ESI) m/z: [M + H]+ calcd for C24H21BrN3O3, 478.0761;
found, 478.0760.
2-Bromo-N-(2-(tert-butylamino)-2-oxo-1-(pyridin-2-yl)ethyl)-4-
methoxybenzamide (5q). It was synthesized according to procedure
A on a 2 mmol scale (235 mg, 28%) as a brown solid; mp: 164−165
°C; Rf = 0.36 (50% EtOAc/petroleum ether).
1H NMR (500 MHz,
chloroform-d) δ 8.55 (d, J = 5.0 Hz, 1H), 8.15 (d, J = 5.9 Hz, 1H),
7.72 (t, J = 7.9 Hz, 1H), 7.65 (d, J = 8.6 Hz, 1H), 7.57 (d, J = 7.9 Hz,
1H), 7.25 (t, J = 6.3 Hz, 1H), 7.16 (s, 2H), 6.93−6.85 (m, 1H), 5.65
(d, J = 5.8 Hz, 1H), 3.83 (s, 3H), 1.31 (s, 9H). 13C{1H} NMR (126
MHz, chloroform-d) δ 167.2, 166.7, 161.4, 156.2, 148.6, 137.4, 131.5,
128.8, 123.0, 121.2, 120.5, 118.9, 113.4, 59.1, 55.7, 51.7, 28.6. HRMS
(ESI) m/z: [M + H]+ calcd for C19H23BrN3O3, 420.0917; found,
420.0916.
2-Bromo-N-(1-(tert-butylamino)-4-(methylthio)-1-oxobutan-2-
yl)-5-methylbenzamide (5r). It was synthesized according to
procedure A on a 2 mmol scale (256 mg, 32%) as a yellow solid;
mp: 178−179 °C; Rf = 0.42 (30% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 7.43 (d, J = 8.2 Hz, 1H), 7.16 (d, J = 8.1
Hz, 1H), 7.06 (dd, J = 8.2, 2.2 Hz, 1H), 6.69 (s, 1H), 4.78 (dt, J = 8.1,
6.7 Hz, 1H), 2.61 (dddd, J = 41.8, 13.3, 8.7, 6.3 Hz, 2H), 2.30 (s,
3H), 2.21−2.03 (m, 5H), 1.34 (s, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 169.8, 167.7, 137.6, 136.9, 133.1, 132.2, 130.0, 116.0,
53.2, 51.6, 31.9, 30.2, 28.7, 20.8, 15.3. HRMS (ESI) m/z: [M + H]+
calcd for C17H26BrN2O2S, 401.0893; found, 401.0890.
2-Bromo-N-(2-(tert-butylamino)-1-(4-chlorophenyl)-2-oxoethyl)-
4-methylbenzamide (5s). It was synthesized according to procedure
A on a 2 mmol scale (349 mg, 40%) as a yellow solid; mp: 199−200
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°C; Rf = 0.49 (20% EtOAc/petroleum ether). 1H NMR (500 MHz,
chloroform-d) δ 7.62 (d, J = 7.0 Hz, 1H), 7.49−7.41 (m, 4H), 7.35−
7.30 (m, 2H), 7.18−7.13 (m, 1H), 6.35 (s, 1H), 5.74 (d, J = 7.0 Hz,
1H), 2.37 (s, 3H), 1.27 (s, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 168.3, 166.8, 142.3, 136.9, 134.0, 133.7, 129.7, 129.0,
128.7, 128.2, 119.4, 57.2, 51.9, 28.5, 21.0. HRMS (ESI) m/z: [M +
H]+ calcd for C20H23BrClN2O2, 437.0626; found, 437.0625.
2-Bromo-N-(2-(tert-butylamino)-2-oxoethyl)-4-nitrobenzamide
(5t). It was synthesized according to procedure A on a 2 mmol scale
(214 mg, 30%) as a white solid; mp: 169−170 °C; Rf = 0.21 (50%
EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 8.49
(d, J = 2.1 Hz, 1H), 8.23 (dd, J = 8.4, 2.2 Hz, 1H), 7.70 (d, J = 8.4 Hz,
1H), 7.21 (t, J = 4.8 Hz, 1H), 6.09 (s, 1H), 4.09 (d, J = 4.7 Hz, 2H),
1.39 (s, 9H). 13C{1H} NMR (126 MHz, chloroform-d) δ 166.7,
166.1, 148.7, 142.8, 130.1, 128.5, 122.5, 120.3, 52.0, 44.1, 28.7.
HRMS (ESI) m/z: [M + H]+ calcd for C13H17BrN3O4, 358.0397;
found, 358.0398.
N-(2-(tert-Butylamino)-2-oxoethyl)-2-chloroquinoline-3-carbox-
amide (5u). It was synthesized according to procedure A on a 2 mmol
scale (255 mg, 40%) as a white solid; mp: 187−188 °C; Rf = 0.56
(80% EtOAc/petroleum ether). 1H NMR (500 MHz, chloroform-d)
δ 8.45 (d, J = 12.3 Hz, 1H), 8.00 (t, J = 7.5 Hz, 1H), 7.89−7.74 (m,
3H), 7.64−7.51 (m, 1H), 6.45 (d, J = 43.1 Hz, 1H), 4.15 (d, J = 5.0
Hz, 2H), 1.39 (d, J = 3.8 Hz, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 167.2, 165.4, 147.9, 146.0, 139.7, 132.1, 128.4 (d, J =
4.1 Hz), 128.2, 127.9, 126.2, 51.8, 44.5, 28.7. HRMS (ESI) m/z: [M +
H]+ calcd for C16H19ClN3O2, 320.1160; found, 320.1160.
2-Bromo-N-(2-(tert-butylamino)-2-oxoethyl)thiophene-3-car-
boxamide (5v). It was synthesized according to procedure A on a 2
mmol scale (286 mg, 45%) as a white solid; mp: 165−166 °C; Rf =
0.65 (80% EtOAc/petroleum ether). 1H NMR (500 MHz, chloro-
form-d) δ 7.62 (t, J = 4.3 Hz, 1H), 7.35 (d, J = 5.8 Hz, 1H), 7.25 (d, J
= 5.8 Hz, 1H), 6.52 (s, 1H), 4.12 (d, J = 4.6 Hz, 2H), 1.40 (s, 9H).
13C{1H} NMR (126 MHz, chloroform-d) δ 167.7, 162.4, 135.1,
129.2, 126.2, 113.6, 51.7, 44.2, 28.8. HRMS (ESI) m/z: [M + H]+
calcd for C11H16BrN2O2S, 319.0110; found, 319.0111.
N-(tert-Butyl)-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)acetamide (7aa). It was synthesized according to
procedure B on a 0.3 mmol scale (76 mg, 70%) as a red solid; mp:
256−257 °C; Rf = 0.48 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 8.66 (t, J = 7.9 Hz, 1H), 8.31 (t, J = 7.0
Hz, 1H), 7.87 (d, J = 7.8 Hz, 1H), 7.72 (q, J = 7.0 Hz, 1H), 7.56 (d, J
= 6.9 Hz, 1H), 7.44 (dt, J = 12.1, 6.9 Hz, 2H), 7.38−7.31 (m, 1H),
6.47 (s, 1H), 5.05 (s, 2H), 1.36 (s, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 190.6, 166.0, 164.1, 155.8, 137.0, 134.5, 134.3, 133.6,
132.5, 131.0, 128.5, 127.3, 123.6, 123.2, 123.1, 123.0, 109.1, 52.0,
49.5, 28.7. HRMS (ESI) m/z: [M + H]+ calcd for C22H21N2O3,
361.1547; found, 361.1547.
N-(tert-Butyl)-2-(8,9-dimethoxy-5,11-dioxo-5,11-dihydro-6H-
indeno[1,2-c]isoquinolin-6-yl)acetamide (7ab). It was synthesized
according to procedure B on a 0.3 mmol scale (81 mg, 64%) as a red
solid; mp: 262−263 °C; Rf = 0.50 (50% EtOAc/petroleum ether). 1H
NMR (500 MHz, chloroform-d) δ 8.58 (dt, J = 8.2, 0.8 Hz, 1H),
8.32−8.17 (m, 1H), 7.77 (s, 1H), 7.70 (ddd, J = 8.4, 7.1, 1.4 Hz, 1H),
7.42 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.12 (s, 1H), 6.62 (s, 1H), 4.99
(s, 2H), 4.06 (s, 3H), 3.96 (s, 3H), 1.35 (s, 9H). 13C{1H} NMR (126
MHz, chloroform-d) δ 190.4, 166.8, 164.4, 155.6, 152.5, 150.6, 134.3,
132.8, 130.5, 128.5, 127.6, 126.7, 123.1, 122.5, 108.5, 108.3, 107.3,
56.9, 56.3, 51.8, 50.6, 28.6. HRMS (ESI) m/z: [M + H]+ calcd for
C24H25N2O5, 421.1758; found, 421.1758.
N-Butyl-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)acetamide (7b). It was synthesized according to
procedure B on a 0.3 mmol scale (73 mg, 68%) as a red solid; mp:
259−260 °C; Rf = 0.54 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 8.81−8.53 (m, 1H), 8.40−8.22 (m, 1H),
7.98 (d, J = 7.5 Hz, 1H), 7.75 (ddd, J = 8.3, 7.1, 1.3 Hz, 1H), 7.59
(dd, J = 7.1, 1.2 Hz, 1H), 7.54−7.41 (m, 2H), 7.38 (t, J = 7.4 Hz,
1H), 6.69 (s, 1H), 5.14 (s, 2H), 3.30 (q, J = 6.8 Hz, 2H), 1.50 (dd, J =
8.5, 6.2 Hz, 2H), 1.37−1.29 (m, 2H), 0.89 (t, J = 7.3 Hz, 3H).
13C{1H} NMR (126 MHz, chloroform-d) δ 190.6, 167.0, 164.3,
155.6, 136.9, 134.5, 134.4, 133.7, 132.5, 131.2, 128.5, 127.5, 123.7,
123.3, 123.2, 123.1, 109.3, 49.1, 39.6, 31.4, 20.0, 13.7. HRMS (ESI)
m/z: [M + H]+ calcd for C22H21N2O3, 361.1547; found, 361.1547.
N-Cyclohexyl-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)acetamide (7c). It was synthesized according to
procedure B on a 0.3 mmol scale (60 mg, 52%) as a red solid; mp:
321−322 °C; Rf = 0.46 (70% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 8.57 (d, J = 8.1 Hz, 1H), 8.40 (d, J = 7.8 Hz,
1H), 8.21 (d, J = 8.0 Hz, 1H), 7.84 (t, J = 7.9 Hz, 1H), 7.64−7.40 (m,
5H), 5.18 (s, 2H), 3.58 (s, 1H), 1.85−1.50 (m, 4H), 1.54 (d, J = 9.3
Hz, 1H), 1.25 (q, J = 10.7 Hz, 5H). 13C{1H} NMR (126 MHz,
DMSO-d6) δ 190.5, 165.5, 162.9, 157.6, 137.4, 134.7, 134.7 (d, J =
24.1 Hz), 134.0, 132.3, 131.8, 128.7, 127.7, 123.3, 123.2, 123.1, 107.3,
48.4, 47.0, 32.7, 25.6, 24.9. HRMS (ESI) m/z: [M + H]+ calcd for
C24H23N2O3, 387.1703; found, 387.1704.
N-Benzyl-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)acetamide (7d). It was synthesized according to
procedure B on a 0.3 mmol scale (47 mg, 40%) as a red solid; mp:
289−290 °C; Rf = 0.55 (70% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 9.00 (t, J = 6.0 Hz, 1H), 8.59 (d, J = 8.0 Hz,
1H), 8.24 (d, J = 8.0 Hz, 1H), 7.91−7.81 (m, 1H), 7.63−7.54 (m,
2H), 7.48 (d, J = 2.5 Hz, 3H), 7.35−7.29 (m, 2H), 7.25 (d, J = 6.3
Hz, 3H), 5.27 (s, 2H), 4.35 (d, J = 5.9 Hz, 2H). 13C{1H} NMR (126
MHz, DMSO-d6) δ 190.5, 166.8, 163.0, 157.5, 139.4, 137.3, 134.8 (d,
J = 8.4 Hz), 134.6, 134.1, 132.4, 131.8, 128.8, 128.7, 127.7, 127.4,
123.4, 123.3, 123.1 (d, J = 5.1 Hz), 107.5, 47.4, 42.8. HRMS (ESI) m/
z: [M + H]+ calcd for C25H19N2O3, 395.1390; found, 395.1389.
N-(4-Chlorobenzyl)-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-
c]isoquinolin-6-yl)acetamide (7e). It was synthesized according to
procedure B on a 0.3 mmol scale (103 mg, 80%) as a red solid; mp:
291−292 °C; Rf = 0.42 (80% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 9.01 (t, J = 6.0 Hz, 1H), 8.55 (d, J = 8.0 Hz,
1H), 8.20 (d, J = 8.0 Hz, 1H), 7.83 (t, J = 7.6 Hz, 1H), 7.58−7.52 (m,
2H), 7.49−7.43 (m, 3H), 7.36 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.1
Hz, 2H), 5.23 (s, 2H), 4.32 (d, J = 5.9 Hz, 2H). 13C{1H} NMR (126
MHz, DMSO-d6) δ 190.4, 166.9, 162.9, 157.3, 138.5, 137.2, 134.7 (d,
J = 6.7 Hz), 134.5, 134.0, 132.3, 132.0, 131.7, 129.6, 128.7, 127.7,
123.3, 123.3, 123.2−122.9 (m), 107.5, 47.3, 42.2. HRMS (ESI) m/z:
[M + H]+ calcd for C25H18ClN2O3, 429.1001; found, 429.0999. [M +
Na]+ calcd for C25H17ClN2O3Na, 451.0820; found, 451.0819.
2-(5,11-Dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-N-
(4-phenoxyphenyl)propanamide (7f). It was synthesized according
to procedure B on a 0.3 mmol scale (96 mg, 66%) as a red solid; mp:
255−256 °C; Rf = 0.66 (40% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 9.76 (s, 1H), 8.62 (d, J = 8.0 Hz, 1H), 8.15
(s, 1H), 7.94 (s, 1H), 7.83 (d, J = 7.1 Hz, 1H), 7.67−7.47 (m, 6H),
7.36 (t, J = 7.8 Hz, 2H), 7.10 (t, J = 7.5 Hz, 1H), 6.96 (d, J = 8.1 Hz,
4H), 5.58 (s, 1H), 1.78 (d, J = 6.6 Hz, 3H). 13C{1H} NMR (126
MHz, DMSO-d6) δ 190.7, 167.1, 162.6, 157.8, 152.3, 137.4, 135.4,
134.8, 134.5 (d, J = 28.0 Hz), 132.4, 131.7, 130.4, 128.4, 127.7, 124.2
(d, J = 10.1 Hz), 123.8, 123.5, 123.2 (d, J = 20.1 Hz), 122.1, 119.7,
118.4, 108.5, 57.5, 15.4. HRMS (ESI) m/z: [M + Na]+ calcd for
C31H22N2O4Na, 509.1472; found, 509.1470.
N-(tert-Butyl)-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)-3-methylbutanamide (7g). It was synthesized
according to procedure B on a 0.3 mmol scale (74 mg, 61%) as a
red solid; mp: 249−250 °C; Rf = 0.44 (10% EtOAc/petroleum ether).
1H NMR (500 MHz, chloroform-d) δ 8.77 (d, J = 8.1 Hz, 1H), 8.68
(s, 1H), 8.52 (d, J = 7.6 Hz, 1H), 8.36 (dd, J = 8.2, 1.3 Hz, 1H),
7.82−7.77 (m, 1H), 7.65 (dd, J = 7.1, 1.3 Hz, 1H), 7.58−7.49 (m,
2H), 7.41 (t, J = 7.4 Hz, 1H), 4.67 (d, J = 10.8 Hz, 1H), 3.32−3.21
(m, 1H), 1.42 (s, 9H), 1.18 (d, J = 6.6 Hz, 3H), 0.68 (d, J = 6.5 Hz,
3H). 13C{1H} NMR (126 MHz, chloroform-d) δ 190.9, 168.7, 165.7,
157.3, 137.5, 134.5, 134.4, 134.1, 132.3, 130.8, 128.2, 127.5, 124.7,
124.1, 123.6, 123.2, 110.4, 75.3, 51.2, 29.7, 28.6, 19.8. HRMS (ESI)
m/z: [M + H]+ calcd for C25H27N2O3, 403.2016; found, 403.2015.
2-(5,11-Dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-N-
(2-ethylphenyl)pentanamide (7h). It was synthesized according to
procedure B on a 0.3 mmol scale (93 mg, 69%) as a red solid; mp:
285−286 °C; Rf = 0.64 (30% EtOAc/petroleum ether). 1H NMR
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(500 MHz, chloroform-d) δ 10.24 (s, 1H), 8.77 (d, J = 8.1 Hz, 1H),
8.41 (d, J = 8.2 Hz, 1H), 8.34 (d, J = 7.6 Hz, 1H), 8.01 (d, J = 8.0 Hz,
1H), 7.82 (t, J = 7.6 Hz, 1H), 7.67 (d, J = 7.1 Hz, 1H), 7.55 (m, J =
7.7, 2.9 Hz, 2H), 7.43 (t, J = 7.4 Hz, 1H), 7.24 (d, J = 7.8 Hz, 2H),
7.14 (t, J = 7.4 Hz, 1H), 5.47 (dd, J = 9.2, 6.3 Hz, 1H), 2.82−2.76 (m,
1H), 2.74 (d, J = 7.6 Hz, 2H), 2.55−2.44 (m, 1H), 1.36−1.31 (m,
2H), 1.25 (t, J = 7.5 Hz, 3H), 0.93 (t, J = 7.3 Hz, 3H). 13C{1H} NMR
(126 MHz, chloroform-d) δ 190.8, 168.9, 165.8, 156.7, 137.3, 135.1,
135.0, 134.7, 134.3, 134.1, 133.6, 132.3, 131.1, 128.9, 128.2, 127.8,
126.6, 125.4, 124.1, 123.7, 123.5, 122.9, 110.7, 67.7, 31.5, 24.8, 19.8,
14.3, 13.4. HRMS (ESI) m/z: [M + Na]+ calcd for C29H26N2O3Na,
473.1836; found, 473.1834.
N-(2,3-Dimethoxybenzyl)-2-(5,11-dioxo-5,11-dihydro-6H-
indeno[1,2-c]isoquinolin-6-yl)-4-methylpentanamide (7i). It was
synthesized according to procedure B on a 0.3 mmol scale (110
mg, 72%) as a red solid; mp: 301−302 °C; Rf = 0.58 (50% EtOAc/
petroleum ether). Mixture of rotamers (ratio, 3:2); 1H NMR (500
MHz, chloroform-d) δ 8.71 (dd, J = 20.7, 6.9 Hz, 1H), 8.33 (dd, J =
20.5, 7.7 Hz, 1.6H), 8.14 (d, J = 7.2 Hz, 0.6H), 7.75 (t, J = 7.6 Hz,
1H), 7.61 (d, J = 7.0 Hz, 0.6H), 7.58−7.43 (m, 2H), 7.39 (t, J = 7.3
Hz, 0.6H), 7.33 (d, J = 7.5 Hz, 0.4H), 7.26 (t, J = 7.3 Hz, 0.4H), 7.19
(t, J = 7.6 Hz, 0.4H), 7.03 (t, J = 7.9 Hz, 0.6H), 6.94 (d, J = 7.6 Hz,
0.6H), 6.86 (t, J = 7.3 Hz, 1H), 6.73 (t, J = 8.0 Hz, 0.8H), 6.63−6.54
(m, 0.8H), 5.43 (dd, J = 10.0, 5.1 Hz, 0.6H), 4.66 (dd, J = 15.4, 6.0
Hz, 0.6H), 4.56−4.43 (m, 1H), 4.39 (dd, J = 14.6, 5.3 Hz, 0.4H), 3.87
(d, J = 11.7 Hz, 3.6H), 3.75 (s, 1.2H), 3.62 (s, 1.2H), 2.71 (ddd, J =
14.3, 9.6, 5.0 Hz, 0.6H), 2.62−2.49 (m, 0.4H), 2.09 (td, J = 10.9, 8.2,
4.2 Hz, 0.6H), 1.94 (ddd, J = 14.3, 9.8, 4.5 Hz, 0.4H), 1.72 (s, 0.4H),
1.53 (d, J = 9.0 Hz, 0.6H), 1.39−1.31 (m, 1H), 1.02 (d, J = 6.4 Hz,
1.2H), 0.87 (d, J = 6.6 Hz, 1.8H), 0.83 (d, J = 6.6 Hz, 1.2H), 0.78 (d,
J = 6.5 Hz, 1.8H). 13C{1H} NMR (126 MHz, chloroform-d, major
rotamer) δ 190.7, 170.1, 165.2, 156.9, 152.6, 147.2, 137.3, 134.4,
134.0, 133.2, 132.2, 131.5, 131.0, 130.4, 128.2, 127.5, 124.1, 123.7,
123.4, 122.6, 120.9, 111.9, 110.3, 64.4, 60.8, 55.8, 38.9, 37.6, 25.2,
22.9, 21.4. HRMS (ESI) m/z: [M + H]+ calcd for C31H31N2O5,
511.2228; found, 511.2225.
N-Benzyl-2-cyclopentyl-2-(5,11-dioxo-5,11-dihydro-6H-indeno-
[1,2-c]isoquinolin-6-yl)acetamide (7j). It was synthesized according
to procedure B on a 0.3 mmol scale (104 mg, 75%) as a red solid; mp:
262−263 °C; Rf = 0.81 (40% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 8.87 (t, J = 6.0 Hz, 1H), 8.74 (d, J = 8.0
Hz, 1H), 8.37 (d, J = 7.7 Hz, 1H), 8.31 (dd, J = 8.3, 1.3 Hz, 1H), 7.78
(ddd, J = 8.3, 7.1, 1.4 Hz, 1H), 7.65 (dd, J = 7.1, 1.3 Hz, 1H), 7.53
(dtd, J = 12.0, 7.4, 1.3 Hz, 2H), 7.41 (t, J = 7.4 Hz, 1H), 7.36 (s, 1H),
7.32−7.27 (m, 2H), 5.00 (d, J = 10.9 Hz, 1H), 4.72 (dd, J = 15.1, 6.6
Hz, 1H), 4.39 (dd, J = 15.1, 5.2 Hz, 1H), 1.95 (ddd, J = 12.6, 7.6, 5.0
Hz, 1H), 1.78−1.35 (m, 8H). 13C{1H} NMR (126 MHz, chloroform-
d) δ 190.8, 170.0, 165.7, 156.9, 138.2, 137.4, 134.5, 134.5, 134.1,
132.3, 131.0, 128.7, 128.1, 127.6, 127.5, 127.4, 124.2, 124.0, 123.6,
123.3, 110.3, 71.9, 43.5, 39.1, 30.6, 25.4, 24.6. HRMS (ESI) m/z: [M
+ H]+ calcd for C30H27N2O3, 463.2016; found, 463.2017.
2-(5,11-Dioxo-5,11-dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)-4-
phenyl-N-(2,4,4-trimethylpentan-2-yl)butanamide (7k). It was
synthesized according to procedure B on a 0.3 mmol scale (101
mg, 65%) as a red solid; mp: 274−275 °C; Rf = 0.65 (20% EtOAc/
petroleum ether). Mixture of rotamers (ratio, 3:1); 1H NMR (500
MHz, chloroform-d) δ 8.75 (d, J = 8.1 Hz, 1H), 8.36 (dd, J = 8.1, 1.3
Hz, 1H), 7.98 (s, 0.75H), 7.85 (d, J = 6.8 Hz, 0.75H), 7.80 (td, J =
7.0, 1.7 Hz, 1H), 7.69 (d, J = 7.5 Hz, 0.25H), 7.60 (ddd, J = 14.2, 6.6,
1.7 Hz, 1H), 7.56−7.50 (m, 1H), 7.46−7.31 (m, 2H), 7.13−6.88 (m,
5H), 6.39 (dd, J = 10.0, 3.3 Hz, 0.25H), 5.79 (s, 0.25H), 5.05 (dd, J =
9.9, 4.3 Hz, 0.75H), 3.06 (dq, J = 11.7, 6.8, 4.0 Hz, 1H), 2.80 (dt, J =
14.5, 7.4 Hz, 0.25H), 2.69 (dq, J = 9.4, 5.9, 3.1 Hz, 1.5H), 2.56 (dt, J
= 14.7, 7.6 Hz, 0.25H), 2.42 (dq, J = 19.3, 7.8, 6.4 Hz, 1H), 1.95−
1.71 (m, 1.5H), 1.68 (d, J = 10.3 Hz, 0.5H), 1.45 (d, J = 4.7 Hz,
4.5H), 1.38 (s, 1H), 1.27 (d, J = 5.5 Hz, 1.5H), 0.95 (s, 6.75H), 0.81
(s, 2.25H). 13C{1H} NMR (126 MHz, chloroform-d, major rotamer)
δ 190.8, 168.7, 165.3, 157.1, 138.9, 137.2, 134.5, 134.2, 133.8, 132.3,
130.7, 128.4, 128.4, 128.2, 127.5, 126.3, 124.0, 123.7, 123.6, 123.1,
110.2, 66.3, 55.4, 51.5, 32.4, 31.4, 30.0, 29.2, 29.0. HRMS (ESI) m/z:
[M + H]+ calcd for C34H37N2O3, 521.2799; found, 521.2795.
Methyl (2-(5,11-Dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)-2-phenylacetyl)glycinate (7l). It was synthesized
according to procedure B on a 0.3 mmol scale (80 mg, 59%) as a red
solid; mp: 255−256 °C; Rf = 0.50 (50% EtOAc/petroleum ether). 1H
NMR (500 MHz, chloroform-d) δ 8.76 (d, J = 8.1 Hz, 1H), 8.33 (d, J
= 8.1, 1.3 Hz, 1H), 7.85−7.70 (m, 1H), 7.67−7.59 (m, 1H), 7.50 (m,
J = 19.0, 7.4 Hz, 6H), 7.42 (t, J = 7.2 Hz, 1H), 7.35−7.31 (m, 2H),
7.05 (d, J = 5.5 Hz, 1H), 6.55 (s, 1H), 4.35 (dd, J = 18.3, 6.2 Hz, 1H),
4.01 (dd, J = 18.3, 4.1 Hz, 1H), 3.77 (s, 3H). 13C{1H} NMR (126
MHz, chloroform-d) δ 190.6, 170.0, 168.1, 164.3, 156.4, 137.1, 134.6,
134.5, 133.4, 133.2, 132.4, 131.0, 129.5, 129.1, 128.7, 127.6, 127.5,
124.1, 123.7, 123.5, 122.8, 110.2, 66.2, 52.5, 41.8. HRMS (ESI) m/z:
[M + H]+ calcd for C27H21N2O5, 453.1445; found, 453.1446. [M +
Na]+ calcd for C27H20N2O5Na, 475.1264; found, 475.1263.
N-(tert-Butyl)-2-(5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)-2-(4-methoxyphenyl)acetamide (7m). It was
synthesized according to procedure B on a 0.3 mmol scale (78 mg,
56%) as a red solid; mp: 259−260 °C; Rf = 0.38 (30% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 8.76 (d, J =
8.1 Hz, 1H), 8.33 (dd, J = 8.0, 1.3 Hz, 1H), 7.78 (ddd, J = 8.3, 7.2, 1.3
Hz, 1H), 7.66−7.60 (m, 1H), 7.57−7.52 (m, 1H), 7.50 (ddd, J = 8.3,
7.1, 1.2 Hz, 1H), 7.40−7.31 (m, 4H), 6.95 (d, J = 8.8 Hz, 2H), 6.48
(s, 1H), 3.83 (s, 3H), 1.39 (s, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 190.7, 167.3, 164.4, 159.6, 156.9, 137.3, 134.6, 134.3,
133.4, 132.4, 130.9, 128.7, 128.6, 127.4, 125.9, 124.3, 123.7, 123.3,
123.1, 114.6, 109.9, 55.3, 52.0, 29.7, 28.6. HRMS (ESI) m/z: [M +
H]+ calcd for C29H27N2O4, 467.1965; found, 467.1959.
N-Benzyl-2-(3-methoxy-5,11-dioxo-5,11-dihydro-6H-indeno[1,2-
c]isoquinolin-6-yl)acetamide (7n). It was synthesized according to
procedure B on a 0.3 mmol scale (79 mg, 62%) as a red solid; mp:
299−300 °C; Rf = 0.72 (80% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 8.98 (t, J = 6.0 Hz, 1H), 8.45 (d, J = 8.8 Hz,
1H), 7.57 (d, J = 2.8 Hz, 1H), 7.50 (dd, J = 5.5, 2.8 Hz, 1H), 7.44
(dd, J = 8.9, 2.8 Hz, 1H), 7.42−7.37 (m, 3H), 7.31 (t, J = 7.4 Hz,
2H), 7.25 (d, J = 8.1 Hz, 3H), 5.21 (s, 2H), 4.34 (d, J = 5.8 Hz, 2H),
3.87 (s, 3H). 13C{1H} NMR (126 MHz, DMSO-d6) δ 190.6, 166.8,
162.6, 158.8, 155.1, 139.5, 137.6, 134.4, 134.0, 131.3, 128.8, 127.7,
127.4, 126.2, 124.9, 124.8, 124.3, 123.0, 122.9, 109.3, 107.8, 55.9,
47.4, 42.8. HRMS (ESI) m/z: [M + H]+ calcd for C26H21N2O4,
425.1496; found, 425.1496.
2-(4-Bromophenyl)-2-(3-methoxy-5,11-dioxo-5,11-dihydro-6H-
indeno[1,2-c]isoquinolin-6-yl)-N-phenethylacetamide (7o). It was
synthesized according to procedure B on a 0.3 mmol scale (87 mg,
49%) as a red solid; mp: 274−275 °C; Rf = 0.51 (40% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 8.67 (d, J =
8.8 Hz, 1H), 7.68 (d, J = 2.7 Hz, 1H), 7.61−7.55 (m, 1H), 7.47 (d, J
= 7.7 Hz, 3H), 7.40 (dd, J = 8.9, 2.7 Hz, 1H), 7.29 (s, 1H), 7.25−7.10
(m, 8H), 6.74 (s, 1H), 6.35 (s, 1H), 3.93 (s, 3H), 3.66 (s, 2H), 2.87
(s, 2H). 13C{1H} NMR (126 MHz, chloroform-d) δ 190.7, 167.5,
164.0, 159.3, 153.7, 138.3, 137.3, 134.2, 133.5, 132.8, 132.3, 130.6,
128.9, 128.7, 128.6, 126.6, 126.4, 125.4, 125.1, 123.5, 122.7, 122.5(d,
J = 12.1 Hz), 110.6, 108.5, 55.7, 41.0, 35.2, 29.7. HRMS (ESI) m/z:
[M + H]+ calcd for C33H26BrN2O4, 593.1071; found, 593.1070.
N-(4-Cyanobenzyl)-2-(2-methoxy-5,11-dioxo-5,11-dihydro-6H-
indeno[1,2-c]isoquinolin-6-yl)-2-phenylacetamide (7p). It was
synthesized according to procedure B on a 0.3 mmol scale (55 mg,
35%) as a red solid; mp: 283−284 °C; Rf = 0.54 (50% EtOAc/
petroleum ether). 1H NMR (500 MHz, DMSO-d6) δ 8.57 (s, 1H),
8.19 (d, J = 8.9 Hz, 1H), 8.09 (s, 1H), 7.68 (d, J = 7.4 Hz, 2H), 7.50
(dd, J = 27.1, 7.3 Hz, 4H), 7.37 (m, J = 7.7 Hz, 5H), 7.31 (m, J = 7.3
Hz, 2H), 7.18 (dd, J = 8.8, 2.5 Hz, 1H), 4.49 (dd, J = 15.8, 6.2 Hz,
1H), 4.24 (dd, J = 16.0, 5.5 Hz, 1H), 3.94 (s, 3H). 13C{1H} NMR
(126 MHz, DMSO-d6) δ 190.7, 167.5, 164.4, 162.8, 158.2, 145.7,
136.8, 134.6, 134.5, 134.4, 133.8, 132.5, 132.4, 131.65 (d, J = 4.5 Hz),
131.1, 128.6, 128.1, 124.4, 123.0, 119.4, 117.8, 117.0, 109.8, 108.7,
104.5, 56.2, 56.1, 43.1. HRMS (ESI) m/z: [M + H]+ calcd for
C33H24N3O4, 526.1761; found, 526.1755. [M + Na]
+ calcd for
C33H23N3O4Na, 548.1581; found, 548.1574.
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was synthesized according to procedure B on a 0.3 mmol scale (91
mg, 65%) as a red solid; mp: 252−253 °C; Rf = 0.54 (50% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 9.95 (s, 1H),
8.72 (s, 1H), 8.40−8.17 (m, 2H), 7.78 (s, 1H), 7.67−7.48 (m, 2H),
7.30 (d, J = 4.0 Hz, 1H), 7.20 (t, J = 7.5 Hz, 1H), 7.04 (dd, J = 25.8,
7.9 Hz, 3H), 6.55 (d, J = 7.4 Hz, 1H), 4.03 (s, 3H), 1.43 (s, 9H).
13C{1H} NMR (126 MHz, chloroform-d) δ 191.3, 164.6, 164.4,
163.3, 157.6, 155.9, 148.4, 138.2, 137.8, 134.9, 134.5, 132.0, 131.2,
130.2, 123.4, 122.7, 122.5, 120.3, 117.5, 116.8, 109.1, 104.0, 59.1,
55.8, 51.8, 28.8. HRMS (ESI) m/z: [M + H]+ calcd for C28H26N3O4,
468.1918; found, 468.1913.
N-(tert-Butyl)-2-(3-methyl-5,11-dioxo-5,11-dihydro-6H-indeno-
[1,2-c]isoquinolin-6-yl)-4-(methylthio)butanamide (7r). It was
synthesized according to procedure B on a 0.3 mmol scale (85 mg,
63%) as a red solid; mp: 283−284 °C; Rf = 0.56 (30% EtOAc/
petroleum ether). Mixture of rotamers (ratio, 1:1); 1H NMR (500
MHz, DMSO-d6) δ 8.51 (dd, J = 20.7, 8.2 Hz, 1H), 8.06 (s, 0.5H),
7.97 (s, 0.5H), 7.86 (d, J = 7.7 Hz, 0.5H), 7.68 (dd, J = 18.6, 11.5 Hz,
1.5H), 7.59−7.27 (m, 4H), 6.37 (d, J = 10.0 Hz, 0.5H), 5.31 (s,
0.5H), 2.92 (s, 0.5H), 2.65 (s, 0.5H), 2.45 (d, J = 5.6 Hz, 5.5H), 2.16
(s, 0.5H), 1.96 (d, J = 6.8 Hz, 3H), 1.23 (d, J = 16.5 Hz, 9H).
13C{1H} NMR (126 MHz, DMSO-d6, major rotamer) δ 190.7, 167.1,
162.8, 157.8, 138.1, 137.5, 135.8, 134.2, 133.4, 131.1, 129.9, 127.8,
124.9, 123.8, 123.0, 122.6, 108.6, 61.1, 56.1, 51.3, 31.9, 29.0, 21.6,
15.0. HRMS (ESI) m/z: [M + H]+ calcd for C26H29N2O3S, 449.1893;
found, 449.1893.
N-(tert-Butyl)-2-(4-chlorophenyl)-2-(2-methyl-5,11-dioxo-5,11-
dihydro-6H-indeno[1,2-c]isoquinolin-6-yl)acetamide (7s). It was
synthesized according to procedure B on a 0.3 mmol scale (86 mg,
59%) as a red solid; mp: 261−262 °C; Rf = 0.58 (20% EtOAc/
petroleum ether). 1H NMR (500 MHz, chloroform-d) δ 8.58 (s, 1H),
8.18 (d, J = 8.3 Hz, 1H), 7.64 (dd, J = 6.4, 1.9 Hz, 2H), 7.37 (d, J =
8.2 Hz, 4H), 7.32 (dd, J = 13.0, 8.6 Hz, 4H), 6.43 (s, 1H), 2.56 (s,
3H), 1.39 (s, 9H). 13C{1H} NMR (126 MHz, chloroform-d) δ 190.8,
166.8, 164.3, 156.6, 145.8, 137.2, 134.4, 134.4, 133.6, 132.9, 132.4,
131.0, 129.4, 129.3, 129.2, 128.7, 128.6, 128.4, 123.4, 123.4, 110.1,
52.1, 29.7, 28.5, 22.2. HRMS (ESI) m/z: [M + H]+ calcd for
C29H26ClN2O3, 485.1627; found, 485.1623.
N-(tert-Butyl)-2-(2-nitro-5,11-dioxo-5,11-dihydro-6H-indeno[1,2-
c]isoquinolin-6-yl)acetamide (7t). It was synthesized according to
procedure B on a 0.3 mmol scale (98 mg, 81%) as a red solid; mp:
239−240 °C; Rf = 0.40 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 9.45 (d, J = 2.2 Hz, 1H), 8.47 (d, J = 8.8
Hz, 1H), 8.18 (dd, J = 8.8, 2.3 Hz, 1H), 7.83 (d, J = 7.5 Hz, 1H), 7.63
(dd, J = 6.9, 1.3 Hz, 1H), 7.49 (td, J = 7.6, 1.4 Hz, 1H), 7.43 (t, J =
7.3 Hz, 1H), 6.28 (s, 1H), 5.11 (s, 2H), 1.40 (s, 9H). 13C{1H} NMR
(126 MHz, chloroform-d) δ 189.6, 165.0, 162.9, 157.5, 151.4, 136.5,
134.4, 133.8, 133.1, 131.9, 130.6, 126.3, 123.7, 123.4, 120.7, 119.1,
108.2, 52.3, 49.2, 28.7. HRMS (ESI) m/z: [M + H]+ calcd for
C22H20N3O5, 406.1398; found, 406.1397.
N-(tert-Butyl)-2-(6,13-dioxo-6,13-dihydro-5H-benzo[b]indeno-
[1,2-h][1,6]naphthyridin-5-yl)acetamide (7u). It was synthesized
according to procedure B on a 0.3 mmol scale (69 mg, 56%) as a red
solid; mp: 297−298 °C; Rf = 0.62 (75% EtOAc/petroleum ether). 1H
NMR (500 MHz, DMSO-d6) δ 9.33 (s, 1H), 8.28 (d, J = 8.3 Hz, 1H),
8.25 (s, 1H), 8.15 (d, J = 8.6 Hz, 1H), 8.02−7.94 (m, 1H), 7.68 (dd, J
= 13.5, 7.0 Hz, 2H), 7.63 (d, J = 4.1 Hz, 2H), 7.58 (dd, J = 7.3, 3.9
Hz, 1H), 5.25 (s, 2H), 1.30 (s, 9H). 13C{1H} NMR (126 MHz,
DMSO-d6) δ 188.0, 165.6, 163.7, 161.8, 151.5, 147.6, 139.8, 136.8,
134.5, 133.9, 132.5, 130.5, 129.1, 127.1, 126.3, 124.0, 123.1, 118.3,
108.2, 79.7, 55.4, 51.4, 28.9. HRMS (ESI) m/z: [M + H]+ calcd for
C25H22N3O3, 412.1656; found, 412.1653.
N-(tert-Butyl)-2-(4,10-dioxo-4,10-dihydro-5H-indeno[1,2-b]-
thieno[2,3-d]pyridin-5-yl)acetamide (7v). It was synthesized accord-
ing to procedure B on a 0.3 mmol scale (41 mg, 37%) as a red solid;
mp: 268−269 °C; Rf = 0.55 (60% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 8.03 (d, J = 7.6 Hz, 1H), 7.71−7.60 (m,
2H), 7.50 (td, J = 7.7, 1.3 Hz, 1H), 7.46−7.37 (m, 2H), 6.54 (s, 1H),
5.08 (d, J = 5.3 Hz, 2H), 1.37 (s, 9H). 13C{1H} NMR (126 MHz,
chloroform-d) δ 188.3, 165.9, 160.3, 154.4, 141.8, 137.6, 134.4, 134.1,
131.2, 128.2, 127.1, 124.7, 123.9, 123.5, 110.4, 52.0, 49.4, 28.6.




N-phenethylacetamide (8). It was synthesized according to
procedure C on a 0.1 mmol scale (62 mg, 95%) as a red solid; mp:
305−306 °C; Rf = 0.42 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, chloroform-d) δ 8.70 (d, J = 8.8 Hz, 1H), 7.74 (d, J = 2.7
Hz, 1H), 7.62−7.57 (m, 1H), 7.52 (d, J = 8.1 Hz, 2H), 7.47 (s, 1H),
7.41 (dd, J = 8.9, 2.7 Hz, 1H), 7.34 (d, J = 8.1 Hz, 2H), 7.30 (d, J =
9.0 Hz, 3H), 7.24−7.13 (m, 5H), 7.11 (d, J = 2.1 Hz, 1H), 7.07 (dd, J
= 8.4, 2.2 Hz, 1H), 6.96 (d, J = 8.3 Hz, 1H), 6.58 (s, 1H), 4.33 (s,
4H), 3.94 (s, 3H), 3.67 (q, J = 6.5 Hz, 2H), 2.88 (t, J = 6.9 Hz, 2H).
13C{1H} NMR (126 MHz, chloroform-d) δ 190.8, 167.9, 164.0,
159.2, 154.1, 143.8, 143.6, 140.9, 138.6, 137.6, 134.4, 133.5, 133.4,
132.0, 130.4, 128.7, 128.6, 127.8, 127.4, 126.5 (d, J = 3.1 Hz), 125.7,
125.4, 125.0, 123.3, 122.5, 120.1, 117.7, 115.8, 110.5, 108.6, 64.5 (d, J
= 5.1 Hz), 55.6, 41.1, 35.3. HRMS (ESI) m/z: [M + H]+ calcd for
C41H33N2O6, 649.2333; found, 649.2332. [M + Na]
+ calcd for
C41H32N2O6Na, 671.2153; found, 671.2152.
N-(4-(1H-Tetrazol-5-yl)benzyl)-2-(2-methoxy-5,11-dioxo-5,11-di-
hydro-6H-indeno[1,2-c]isoquinolin-6-yl)-2-phenylacetamide (9). It
was synthesized according to procedure D on a 0.1 mmol scale (47
mg, 82%) as a red solid; mp: 264−265 °C; Rf = 0.46 (15% MeOH/
dichloromethane). 1H NMR (500 MHz, methanol-d4) δ 8.21 (d, J =
9.0 Hz, 1H), 8.02 (d, J = 2.5 Hz, 1H), 7.98−7.91 (m, 2H), 7.57 (d, J
= 7.8 Hz, 2H), 7.46 (t, J = 7.7 Hz, 2H), 7.39 (dd, J = 7.6, 3.4 Hz, 3H),
7.36−7.33 (m, 1H), 7.31 (s, 1H), 7.22 (dd, J = 5.7, 2.6 Hz, 2H), 7.06
(dd, J = 9.0, 2.6 Hz, 1H), 6.87 (s, 1H), 4.66 (d, J = 15.0 Hz, 1H), 4.37
(d, J = 15.0 Hz, 1H), 3.87 (s, 3H). 13C{1H} NMR (126 MHz,
methanol-d4) δ 190.8, 168.6, 164.6, 163.4, 161.2, 157.5, 138.9, 136.5,
134.5, 134.3, 133.6, 132.9, 130.8, 130.2, 128.6, 128.5, 128.1, 128.0,
127.7, 126.4, 123.4, 122.5, 117.4, 116.9, 109.1, 103.8, 54.8, 43.2, 35.2.
HRMS (ESI) m/z: [M + H]+ calcd for C33H25N6O4, 569.1932; found,
569.1926. [M + Na]+ calcd for C33H24N6O4Na, 591.1751; found,
591.1744.
2-(2-Amino-5,11-dioxo-5,11-dihydro-6H-indeno[1,2-c]-
isoquinolin-6-yl)-N-(tert-butyl)acetamide (10). It was synthesized
according to procedure F on a 0.3 mmol scale (108 mg, 96%) as a red
solid; mp: 188−189 °C; Rf = 0.33 (50% EtOAc/petroleum ether). 1H
NMR (500 MHz, DMSO-d6) δ 8.12 (s, 1H), 7.87 (d, J = 8.8 Hz, 1H),
7.63 (d, J = 2.2 Hz, 1H), 7.55−7.47 (m, 2H), 7.42 (dt, J = 7.3, 3.4 Hz,
2H), 6.73 (dd, J = 8.7, 2.3 Hz, 1H), 6.33 (s, 2H), 5.11 (s, 2H), 1.28
(s, 9H). 13C{1H} NMR (126 MHz, DMSO-d6) δ 190.5, 166.1, 162.1,
157.9, 154.5, 137.6, 134.9, 134.3, 133.5, 131.4, 130.5, 123.0, 122.6,
115.7 (d, J = 4.9 Hz), 112.3, 106.7, 103.2 (d, J = 7.4 Hz), 51.2, 46.3,
28.9 (d, J = 5.2 Hz). HRMS (ESI) m/z: [M + H]+ calcd for
C22H22N3O3, 376.1656; found, 376.1654.
2-(2-Amino-5,11-dioxo-5,6a,11,11a-tetrahydro-6H-indeno[1,2-
c]isoquinolin-6-yl)-N-(tert-butyl)acetamide (11). It was synthesized
according to procedure E on a 0.2 mmol scale (44 mg, 58%) as a
white solid; mp: 155−156 °C; Rf = 0.22 (80% EtOAc/petroleum
ether). 1H NMR (500 MHz, methanol-d4) δ 8.04 (d, J = 8.8 Hz, 1H),
7.98 (s, 1H), 7.71−7.65 (m, 1H), 7.63−7.56 (m, 1H), 7.42−7.31 (m,
2H), 7.15 (d, J = 2.3 Hz, 1H), 6.82 (dd, J = 8.8, 2.3 Hz, 1H), 5.50 (s,
1H), 5.19 (s, 2H), 1.39 (s, 9H). 13C{1H} NMR (126 MHz, methanol-
d4) δ 167.7, 163.8, 153.0, 147.8, 140.7, 136.5, 135.8, 129.7, 128.2,
127.5, 124.5, 120.7, 120.3, 115.4, 113.9, 104.3, 71.7, 51.0, 46.2, 29.4,
27.6. HRMS (ESI) m/z: [M + H]+ calcd for C22H24N3O3, 378.1812;
found, 378.1811.
N-(tert-Butyl)-2-(5,11-dioxo-2-(3-phenylureido)-5,11-dihydro-
6H-indeno[1,2-c]isoquinolin-6-yl)acetamide (12). It was synthesized
according to procedure G on a 0.1 mmol scale (32 mg, 64%) as a red
solid; mp: 277−278 °C; Rf = 0.36 (70% EtOAc/petroleum ether). 1H
NMR (500 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.77 (s, 1H), 8.57 (d, J =
2.6 Hz, 1H), 8.17 (s, 1H), 8.11 (d, J = 8.8 Hz, 1H), 7.74 (dd, J = 8.9,
2.2 Hz, 1H), 7.53 (dd, J = 21.7, 7.5 Hz, 4H), 7.46 (d, J = 7.4 Hz, 2H),
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7.33 (t, J = 7.8 Hz, 2H), 7.03 (t, J = 7.3 Hz, 1H), 5.15 (s, 2H), 1.29 (s,
9H). 13C{1H} NMR (126 MHz, DMSO-d6) δ 190.3, 165.8, 162.2,
158.1, 152.6, 145.6, 139.7, 137.4, 134.7, 133.8, 133.4, 131.7, 130.1 (d,
J = 11.0 Hz), 129.3, 123.3, 122.8, 118.9, 118.2, 118.0, 117.2, 109.4 (d,
J = 10.7 Hz), 106.9, 51.3, 46.7, 28.9. HRMS (ESI) m/z: [M + H]+
calcd for C29H27N4O4, 495.2027; found, 495.2026.
tert-Butyl (S)-(1-((6-(2-(tert-Butylamino)-2-oxoethyl)-5,11-dioxo-
6,11-dihydro-5H-indeno[1,2-c]isoquinolin-2-yl)amino)-1-oxo-3-
phenylpropan-2-yl)carbamate (13). It was synthesized according to
procedure H on a 0.1 mmol scale (49 mg, 78%) as a red solid; mp:
298−299 °C; Rf = 0.28 (50% EtOAc/petroleum ether). 1H NMR
(500 MHz, DMSO-d6) δ 10.62 (s, 1H), 8.77 (s, 1H), 8.17 (d, J = 10.9
Hz, 2H), 7.88 (d, J = 9.1 Hz, 1H), 7.55 (dd, J = 19.9, 6.6 Hz, 2H),
7.47 (d, J = 6.8 Hz, 2H), 7.38 (d, J = 7.5 Hz, 2H), 7.34−7.19 (m,
4H), 5.16 (s, 2H), 4.43 (s, 1H), 3.07 (d, J = 14.1 Hz, 1H), 3.00−2.72
(m, 1H), 1.34 (s, 9H), 1.29 (s, 9H). 13C{1H} NMR (126 MHz,
DMSO-d6) δ 190.3, 172.2, 165.7, 162.2, 158.2, 156.0, 144.6, 138.4,
137.4, 134.7, 133.9, 133.2, 131.8, 130.0, 129.8, 128.6, 126.8, 123.4,
123.0 (d, J = 24.2 Hz), 119.3 (d, J = 25.5 Hz), 118.4, 111.4, 106.9,
78.7, 57.2, 51.3, 46.7, 37.7, 28.9 (d, J = 14.0 Hz), 28.7 (d, J = 16.4
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1H and 13C{1H} NMR spectra of compounds 5, 7, and
8−13, along with X-ray crystallographic data for 7a
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Shishkina, S. V.; Dömling, A. Pd-Catalyzed de Novo Assembly of
Diversely Substituted Indole-Fused Polyheterocycles. J. Org. Chem.
2019, 84, 12148−12156.
(10) Thompson, M. J.; Chen, B. Ugi Reactions with Ammonia Offer
Rapid Access to a Wide Range of 5-Aminothiazole and Oxazole
Derivatives. J. Org. Chem. 2009, 74, 7084−7093.
(11) (a) Liu, J.; Zhang, C.; Zhang, Z.; Wen, X.; Dou, X.; Wei, J.;
Qiu, X.; Song, S.; Jiao, N. Nitromethane as a Nitrogen Donor in
Schmidt-type Formation of Amides and Nitriles. Science 2020, 367,
281−285. (b) Lv, Z. J.; Huang, Z.; Zhang, W. X.; Xi, Z. Scandium-
Promoted Direct Conversion of Dinitrogen into Hydrazine
Derivatives via N−C Bond Formation. J. Am. Chem. Soc. 2019, 141,
8773−8777.
(12) Brown, A. L.; Churches, Q. I.; Hutton, C. A. Total Synthesis of
Ustiloxin D Utilizing an Ammonia−Ugi Reaction. J. Org. Chem. 2015,
80, 9831−9837.
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